Background
Inflammation and prostate cancer: which evidences?
The prostate is an immune-competent organ and is normally populated by a small number of inflammatory cells [
1]. In particular regulatory T-cells are mainly located in the fibromuscular stroma and in the peri-glandular area [
2]. The origin of prostatic inflammation can be multifactorial, including bacterial infections, viruses, dietary factors, hormones, autoimmune responses and urine reflux [
1,
3].
The persistence of some of these factors can constitute to chronic prostatic inflammation. Prostate cancer (PC) is now the most common cancer among men. The role of infection or inflammation is sustained in different cancer sites and also in PC. Epidemiologic, histo-pathologic and molecular pathologic studies provide the emerging evidence of the possible role of prostatic inflammation as a factor involved in PC initiation and/or progression [
4‐
6]. Inflammation can play a role in PC carcinogenesis through several mechanisms: causing cellular and genomic damage; promoting cellular turnover; creating a tissue microenvironment inducing cell replication, angiogenesis and tissue repair [
4,
7].
The high prevalence of chronic inflammation in pathological samples of prostate tissue from surgery or prostate biopsy has sustained a possible link between chronic inflammation and PC [
8,
9]. Pro-inflammatory cytokines, inflammatory mediators and growth factors related to inflammation can determine uncontrolled proliferative response, rapidly dividing cells more likely to undergo mutation, as observed in cancer [
7,
10]. Several PC susceptibility genes such as RNASEL, MSR1,MIC1 involved in PC carcinogenesis, encode proteins with functions in response to inflammation, infection and oxidative stress: their mutation may reduce the possibility of preventing carcinogenesis through these pathways [
4,
11]. Some data show that chronic inflammation can induce proliferative events and post-translational DNA modifications in prostate tissue also through oxidative stress [
8,
12]. Repeated tissue damage and oxidative stress related to this event may produce compensatory cellular proliferation with the risk of hyperplastic growth or neoplastic transformation [
13]. It is accepted that prostatic inflammation can generate free radicals such as nitric oxide that can be converted by cyclo-oxigenase enzymes to different eicosanoids and prostaglandins that have been recognized as regulator of prostate cell proliferation [
14]. Normally glutathione transferase activity defends prostate cells against the genomic damage induced by oxidants isolated at sites of inflammation [
8]. The methylation of this gene produce the loss of his protective activity and it could be implicated in the translation from inflammation to pre-neoplastic lesions such as high grade prostatic intraepithelial neoplasia (PIN) and therefore to PC [
14].
As clinical data, a 5-year follow-up study based on prostate biopsies established that chronic inflammation accounts for nearly 20% PC development [
15,
16]. Moreover, inflammatory atrophy was found in about 40% of PC cores in that study. Observations from many lines of research indicate the existence of role of inflammation in prostate carcinogenesis and progression [
17].
Aim
The aim of the present review is to critically analyze the role of prostatic inflammation as a prognostic factor for the progression and aggressiveness of PC. In particular, we did not analyze the relationship between inflammation and PC development or incidence but, we verified data on the association between inflammation and PC aggressiveness, or PC response to therapies.
Our aim is to analyze whether, in cases with PC diagnosis, an association with an inflammatory status may determine a poorer prognosis, higher aggressiveness of the tumor and lower response to therapies. We also try to verify a possible role of prostatic inflammation as a prognostic factor in PC patients, for tumor progression despite surgical, radiotherapic or medical therapies.
Methods
We searched in the Medline and Cochrane Library databases (primary fields: prostate neoplasm and inflammation; secondary fields: aggressiveness, Gleason score, prognostic, radical prostatectomy, radiation therapy, androgen deprivation therapy, CRPC without language restriction from the literature of the last 10 years. We included original articles, clinical trials conducted in humans and reviews.
Our review was divided in different sections analyzing the following items: relationship between inflammation and PC aggressiveness; influence of inflammation on the response to surgery, radiotherapy, androgen deprivation therapies; role of inflammation in CRPC. At the end of each section we critically analyzed data in terms of a possible prognostic role of prostatic inflammation in these specific settings.
Prognostic value of inflammation in prostate cancer submitted to radical prostatectomy
Radical prostatectomy (RP) is the main treatment choice for localized PC. Risk of biochemical and clinical progression is related to different clinical parameters such as Gleason score, preoperative PSA, pathological staging. Currently, RP is the only treatment for localized PC able to show a benefit for OS and cancer-specific survival (CSS), compared with conservative management, as shown in one prospective randomized trial [
51]. Preoperative models for PC risk stratification include D’Amico or Partin tables and they are based on initial PSA values, biopsy Gleason score and clinical T stage.
Klink et al. [
52] analyzed 287 men with PC submitted to RP to explore the association between tumor inflammation, adverse pathology and biochemical progression after surgery. Mild and marked inflammation was found in 53 and 30% of tissue samples respectively. Cases with marked inflammation were significantly more likely to have higher clinical stage, higher PSA, higher percent of cores positive and positive margins. On univariate analysis, increasing inflammation grade was associated with progressively higher risk of positive margins (OR 2.26–3.56), capsular penetration (OR 3.12–3.19), seminal vesicle invasion (OR 4.08–6.83). After adjusting for multiple clinical characteristics, higher grade of inflammation remained significantly associated with risk of capsular penetration, positive margins and seminal vesicle invasion. Overall, increasing inflammation grade was associated with biochemical progression (
p = 0.02). Mild and marked inflammation were associated with 2.18 (95% CI 1.16–4.14) and 2.55 (95% CI 1.31–4.97)—fold greater biochemical progression rate versus no inflammation. However the association of inflammation with biochemical progression rate did not reach statistical significance (
P > 0.2) after adjustment with the other clinical parameters.
Systemic inflammation is a host reaction to carcinogenesis or cancer progression and serum levels of butyrylcholinesterase (BChE) have been reported to reflect the presence of inflammation and other clinical conditions [
53]. Serum levels of BChE has been found to decrease during inflammation. Koie et al. [
54] in a retrospective study reviewed the pathological records of 535 PC patients submitted to RP. The cut-off point for the serum BChE level was determined as 168 IU/L according to previously described methods. Biochemical progression free survival rates were 77.7% in BChE ≥ 168 IU/L (95% CI 115.2–152.2) and 55.0% in BChE < 168 IU/L (95% CI 104.4–131.7;
p < 0.001). On multivariate analysis, initial PSA and serum BChE levels were independent significant predictors of biochemical progression.
Shafique et al. [
55] investigated the role of inflammation-based prognostic scores, the modified Glasgow Prognostic Score (mGPS) and neutrophil-lymphocyte ratio (NLR), to predict progression after RP. The mGPS was constructed by combining C-reactive protein and albumin whereas NLR by calculating the ratio of neutrophils to lymphocytes. Systemic inflammation appeared to have significant prognostic value. The mGPS predicted poorer 5-year overall survival independent to age, PC grade and NLR. Raised mGPS had a significant association with excess risk of death (OR 2.41; 95% CI 1.37–4.23) among aggressive, clinical significant PC.
Critical analysis
Data on a possible prognostic role of prostatic inflammation in the clinical response to RP in PC are limited in the literature (Table
2). As of now, the studies are mainly retrospective, but some findings may suggest that the grade of inflammation in preoperative biopsy specimens could be used to risk-stratify men with PC for risk of biochemical progression after RP [
54,
55]. However, in a multivariate analysis after adjustment with the other clinical parameters (PSA, clinical stage, Gleason score), inflammation did not result an independent predictor. The suggestion that serum markers of systemic inflammation may be independently related to the biochemical progression free survival must be confirmed in prospective studies.
Table 2
OR and 95% CI values of different inflammatory parameters used as prognostic indicators for PC submitted to radical prostatectomy
High grade histological prostatic inflammation | | Phase II study on RP | High grade inflammation and positive surgical margins or capsular penetration or seminal vesicle invasion | 2.26–3.56 | <0.01 |
3.12–3.19 |
4.08–6.83 |
High grade histological prostatic inflammation | | Phase II study on RP | High grade inflammation and biochemical recurrence | 2.55 (1.31–4.97) | 0.02 |
Systemic inflammation on mGPS | | Phase II study on RP | mGPS and risk of death | 2.41 (1.37–4.23) | <0.01 |
Prognostic value of inflammation in prostate cancer treated by radiotherapy
Definitive radiotherapy is a treatment option for localized or locally advanced PC. Clinical parameters related to treatment response and risk of progression are serum PSA, clinical T stage and biopsy Gleason score.
The results of the Glasgow Inflammation Outcome Study [
56,
57] demonstrated that an increased neuthrophil-to-lymphocyte ratio (NLR) had a prognostic value in localized PC. However the study included a rather heterogeneous population of PC patients. Langsenlehner et al. [
58] analyzed 415 consecutive patients with histologically confirmed PC who underwent radiation therapy. Based on previous data, a NLR cutoff of 5 was applied to differentiate between low (<5) and high (≥5) NLR and it was evaluated before the radiotherapy. A significant association between high NLR and decreased progression free survival (
p = 0.015) and decreased overall survival (
p = 0.011) was found. Both univariate and multivariate analysis showed that elevated NLR was associated with decreased clinical progression free survival (HR 3.09; 95% CI 1.64–5.82
p < 0.001) and decreased overall survival (HR 2.16; 95% CI 1.17–3.99;
p = 0.013). The prognostic value of NLR remained significant also after adjustment for other clinical parameters such as Gleason score and clinical stage. Bahig et al. [
59] retrospectively analyzed 950 PC cases submitted to radiotherapy for localized disease. Neutrophil count (median 4.5 × 10
3/μl, range 0.9–12) (HR =1.18;95% CI 1.01–1.37,
p = 0.028) but not NLR (median 3.0, range 0.1–18.4) was associated to overall survival.
Also plateled-to-lymphocyte ratio (PLR) which is calculated as the ratio of plateled count to lymphocyte count has been proposed as an assessable marker of systemic inflammation and has been presented as prognostic marker of different cancers. Langsenlehner et al. [
60] evaluated 374 PC patients treated with external 3D radiotherapy. The optimal cut-off level for PLR was fixed at 190. A high PLR was a significant prognostic factor for metastasis free survival (HR = 2.24 95% CI 1.06–4.76;
p = 0.036), cancer specific survival (HR 3.99;95% CI 1.19–13.4;
p = 0.025) and overall survival (HR 1.87;95% CI 1.02–3.42;
p = 0.044) by multivariate analysis. The prognostic value of PLR remained significant and independent also after adjustment for Gleason score and clinical stage.
Schoenfeld et al. [
61] evaluated association between single nucleotide polymorphisms (SNP) in RNASEL, a gene implicated in inflammation and clinical response of 434 PC cases submitted to radiotherapy. SNP of rs12757998 was associated with a significant decreased risk for biochemical recurrence (HR 0.60; 95% CI 0.40–0.89;
p = 0.02). This association remained significant also after adjustment for Gleason score and clinical stage, or selecting only cases at high risk.
Thurner et al. [
62] in 261 PC patients treated with external 3D conformational radiotherapy, analyzed the prognostic relevance of elevated plasma C-reactive protein (CRP) as a marker of inflammation. The optimal cut-off level for CRP was 8.6 mg/l. An elevated CRP plasma level was associated with decreased cancer specific survival (HR 3.36; 95% CI 1.42–7.91;
p = 0.006) and overall survival (HR 3.24;95% CI 1.84–5.71;
p < 0.001) at univariate and multivariate analysis. No significant association between CRP and Gleason score or tumor stage was found (
p > 0.05). Using ROC curve analysis, the authors calculated ideal cut-off values of CRP in the three risk groups at 8.9,8.4 and 13.4 respectively.
Critical analysis
More clinical data on the relationship between inflammation and response to radiotherapy for PC are present in the literature (Table
3). The populations analyzed are larger and more homogeneous and data are examined by multivariate analysis so to define their independent prognostic value. Markers of systemic inflammation more than marker specific for prostatic inflammation have been examined. In particular NLR but also PLR and CRP showed a significant and independent prognostic value for patients submitted to radiotherapy, either in terms of clinical progression or of overall survival, also after adjustment for Gleason score and clinical stage [
59,
60]. In the intermediate and high risk classes as described by D’Amico et al., NLR and CRP are able to furthermore stratify cases in terms of clinical progression free survival [
62].
Table 3
OR and 95% CI values of different inflammatory parameters used as prognostic indicators for PC submitted to radiotherapy
Systemic inflammation NLR | | Phase II on radiotherapy as primary treatment | NLR and clinical progression free survival or overall survival | 3.09 (1.64–5.82) | <0.001 |
2.16 (1.17–3.99) | 0.013 |
Systemic inflammation PLR | | Phase II study on radiotherapy as primary treatment | PLR and metastasis free survival or cancer specific survival or overall survival | 2.24 (1.06–4.76) | 0.036 |
3.99 (1.19–13.4) | 0.025 |
1.87 (1.02–3.42) | 0.044 |
SNP in RNASEL | | Phase II study on radiotherapy as primary treatment | SNP of rs12757998 and biochemical recurrence | 0.60 (0.40–0.89) | 0.02 |
Systemic inflammation CRP | | Phase II study on radiotherapy as primary treatment | CRP and cancer specific survival or overall survival | 3.36 (1.42–7.91) | 0.006 |
3.24 (1.84–5.71) | <0.001 |
Elevated NLR and CRP levels may reflect increased concentrations of these pro-inflammatory cytokines that create a microenvironment favouring PC proliferation and metastatization despite radiotherapy [
62]. Furthermore, raised CRP concentrations may produces increased serum levels of vascular endothelial growth factor (VEGF) [
63,
64]. However NLR, PLR and CRP are not specific markers of inflammation that might be influenced by several other conditions such as active infection, inflammatory diseases and smoking behaviour independent of PC.
Prognostic value of inflammation in prostate cancer treated by androgen deprivation therapy and in castration resistant PC
Androgen deprivation therapy (ADT) can be achieved by either suppressing the secretion of testicular androgens using a surgical castration via orchiectomy or a medical castration via inhibiting the hypothalamic pituitary axis using LH-RH agonists or antagonists or inhibiting the action of circulating androgens at the level of their receptor using competing compounds known as anti-androgens. In addition, these two methods can be combined to achieve what is known as complete (or maximal or total) androgen blockade (CAB).
An in vivo model demonstrated that during ADT infiltrated of B cells can activate NFkB kinase with the up-regulation of cytokines such as CXCL-1,IL-8,IL-12,TNF alpha. These cytokines activates STAT3 in PC cells and shortens the duration of ADT response promoting tumor cell survival through anti-apoptotic signaling [
21]. These treatments can be involved in the development of a CRPC [
65].
Sharma et al. [
66] analyzed 122 metastatic PC cases treated by ADT and measured in the serum different cytokines such as MCP-1,IL-1,IL-2,IL-6,IL-8 and TNF alpha. On multivariate analysis only IL-8 (HR 1.9;95% CI 1.0–3.5,
p = 0.04) and TNF alpha (HR 2.0;95% CI 1.1–3.5;
p = 0.02) resulted significant and independent predictors of overall survival during ADT.
Treatment options for CRPC have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, radium 233 and different chemotherapic agents. Docetaxel with prednisone remain the standard first-line chemotherapy for treatment of CRPC. Prognostic and predictive biomarkers for response to the different agents are urgently needed so to identify the better therapeutic sequences for each patient. Inflammation in the prostatic microenvironment may also drive CRPC development during ADT.
Templeton et al. [
67] analyzed in 356 metastatic CRPC patients submitted to docetaxel the prognostic role of NLR. In univariate analysis higher performance status, LDH and NLR (HR 1.65, 95% CI 1.25–2.18;
p < 0.001) at baseline were associated with shorter OS. In multivariate analysis the highest statistical significance was obtained when liver metastases, hemoglobin <120 g/L, LDH > 1.2 X ULN and NLR > 3.0 were included in the model.
Similarly Lorente et al. [
68] analyzed the prognostic role of NLR in a phase III study on 755 metastatic CRPC patients submitted to cabazitaxel as second line chemotherapy. Baseline NLR was associated with OS in univariate (HR 2.89;95% CI 2.12–3.94;
p < 0.001) and multivariate analysis (HR 1.91;95% CI 1.31–2.79;
p = 0.001) also adjusted for other clinical parameters. Authors selected a NLR cut-off of 3 as the most appropriate. Patients with a <3 NLR level had a statistically significant higher median OS (15.9 months versus 12.6 months, HR 1.55;95% CI 1.3–1.84;
p < 0.001). than patients with a NLR ≥ 3.
Van Soest et al. [
69] used data from two randomized phase III studies on 2230 men with metastatic CRPC patients submitted to docetaxel, to investigate the prognostic value of NLR. The optimal threshold of NLR for the prediction of OS was set a 2.05. In multivariate analysis both NLR and ADT duration before CRPC patients were associated with an increased risk of death (NLR HR 1.29;95% CI 1.11–1.50;
p < 0.001) after adjustment for the other clinical parameters. Survival curves showed an OS of 26 months (95% CI 23.8–27.8) for men with a NLR < 2.0 and 19.1 months (95% CI 17.7-20.2) for men with a NLR ≥ 2.0. Sonpavde et al. [
70] evaluated the prognostic impact of NLR as a marker for inflammatory and immune state in men with mCRPC following docetaxel. It is shown that NLR may be associated with an independent poor prognostic impact in post-docetaxel patients with mCRPC (1.55 [1.32, 1.83],
P < .001). In particular NLR determination increased the c-statistic from 0.703 to 0.715 in a prognostic model that included LDH levels, hemoglobin, > 1 organ involved by metastatic disease, alkaline phosphatase, the number of prior cycles of docetaxel and progression to docetaxel.
Liao et al. [
71], in 115 metastatic CRPC patients submitted to docetaxel, showed that median progression free survival (9.8 versus 7.5 months;
p < 0.001) and OS (26.5 versus 13.5 months;
p = 0.002) were higher in cases who did not have an elevated CRP than in those with an elevated CRP. In particular in a multivariate analysis, patients with a CRP > 8 mg/l were at significantly higher risk of tumor progression (HR 2.18; 95% CI 1.40–3.40;
p = 0.001) and death (HR 2.0; 95% CI 1.28–3.12;
p = 0.002) than patients with a CRP ≤ 8 mg/l.
Expanding on the utility of a single biomarker, the modified Glasgow Prognostic Score (mGPS) calculated using CRP and albumin levels, has been identified as a powerful marker of systemic inflammation [
72]. Linton et al. analyzed the prognostic value of mGPS and NLR in 220 metastatic CRPC chemotherapy naïve patients but considered for docetaxel treatment [
72]. NLR was not significantly prognostic for OS (HR 0.98;
p = 0.91). On the contrary albumin (HR 0.28; 95% CI 0.14–0.56;
p < 0.01) and CRP (HR 1.22; 95% CI 1.0–1.48;
p = 0.048) were independently prognostic for OS. Combining the two parameters, a statistically significant association (
p < 0.001) was observed between mGPS and lower OS (HR 1.87; 95% CI 1.35–2.59) with a marked decline in survival at higher scores (median survival 23.5 months at mGPS 0; 9.8 months at mGPS 2).
Leibowits-Amit et al. [
73], in 116 metastatic CRPC patients treated with abiraterone, showed that NLR is a significant prognostic factor (OR 0.8; 95% CI 0.6–0.9,
p = 0.05) for prediction of PSA progression. Using a NLR cut-off of 5, at multivariate analysis, a NLR ≤ 5 associated with restricted metastatic spread remained significantly predictor for PSA progression (OR 4.3; 95% CI 1.4–13.3;
p = 0.01).
Critical analysis
Systemic inflammation represents a truly novel and unexplored prognostic variables in CRPC [
74], independent to other clinical parameters such as stage. It does not substitute but rather integrates with established prognostic factors. Pinato et al. [
74] suggested that inflammation may predict not only survival but also cancer-related symptomatic burden (association between NLR and performance status) and risk of chemotherapy-related toxicity (inflammation-related alterations in drug pharmacokinetic).
Data on CRPC are strongly significant and are obtained in large populations from randomized trials. Different phase II and III trials [
66‐
70] used OS and clinical progression free survival as end-points to evaluate the prognostic role of inflammatory variables (Table
4).
Table 4
OR and 95% CI values of different inflammatory parameters used as prognostic indicators in metastatic PC submitted to ADT or in metastatic CRPC
Serum levels IL-8 | | Phase II study in metastatic PC submitted to ADT | IL-8 and overall survival or TNF alpha and overall survival | 1.9 (1.0–3.5) | 0.04 |
2.0 (1.1–3.5) | 0.02 |
Systemic inflammation NLR | | Phase II study on CRPC submitted to docetaxel | NLR and overall survival | 1.65 (1.25–2.18) | <0.001 |
Systemic inflammation and NLR | | Phase II study on CRPC submitted to carbazitaxel | NLR and overall survival | 1.91 (1.31–2.79) | 0.001 |
Systemic inflammation NLR | | Phase III study on CRPC submitted to docetaxel | NLR and risk of death | 1.29 (1.11–1.50) | <0.001 |
Systemic inflammation NLR | | Phase II study on CRPC submitted to sunitinib | NLR and overall survival | 1.55 (1.32–1.83) | <0.01 |
Systemic inflammation NLR | | Phase II study on CRPC submitted to abiraterone | NLR and PSA progression | 4.3 (1.4–13.3) | 0.01 |
Systemic inflammation CRP | | Phase II study on CRPC submitted to docetaxel | CRP and risk of tumor progression or risk of death | 2.18 (1.40–3.40) | 0.001 |
2.0 (1.28–3.12) | 0.002 |
Systemic inflammation mGPS | | Phase II study on CRPC submitted to docetaxel | mGPS and overall survival | 1.87 (1.35–2.59) | <0.001 |
Both NLR and CRP resulted independent and significant predictors of OS and progression free survival in CRPC cases during chemotherapy with Docetaxel and for NLR also during abiraterone . An optimal threshold of NLR for the prediction of OS was set at 2–3 whereas of CRP at 8 [
71].
Externally validated prognostic algorithms, in patients with metastatic CRPC considered for docetaxel, including NLR or CRP have been proposed [
66‐
70].
The results of these studies qualify the NLR as an independent predictor of mortality in CRPC patients and support its incorporation in prognostic models to stratify patients with CRPC.
Conclusions
The high prevalence of chronic inflammation in pathological samples of prostate tissue from surgery or prostate biopsy has sustained a possible link between inflammation and PC. In cases with PC diagnosis, an association with an inflammatory status may determine a poorer prognosis, higher aggressiveness of the tumor and lower response to therapies. These aspects have been analyzed in several clinical trials; however the majority of data are retrospective rather than prospective. Specific markers of prostatic inflammation have not been significantly identified as possible prognostic predictors.
On the contrary, most of data are focused on markers of systemic inflammation. in particular NLR and CRP, that can be easily obtained from the serum. Based on multivariate analysis they resulted independent significant predictors of clinical response to radiotherapy in localized and locally advanced PC or chemotherapy in CRPC cases, also after adjustment for the other clinical parameters. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors. Validated prognostic algorithms including NLR or CRP have been proposed in particular for CRPC cases but prospective clinical trials should confirm these positive data.